# Phase 3 trials for chronic weight management planned for initiation in the second half of 2026.

*business · news · 2026-04-29 · The Manila Times*

## Key points

- Petrelintide will enter Phase 3 trials for chronic weight management in the second half of 2026.
- The ZUPREME-1 Phase 2 trial showed petrelintide achieved double-digit weight loss with placebo-like tolerability.
- A Phase 2 trial of petrelintide combined with enicepatide is planned for the second quarter of 2026.
- Petrelintide is formulated for once-weekly dosing with stability that allows co-formulation with other peptides.

**Companies:** Roche, Zealand Pharma
**Countries:** Denmark, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/30/tmt-newswire/globenewswire/zealand-pharma-and-roche-to-advance-petrelintide-an-amylin-analog-to-phase-3-trials-for-chronic-weight-management/2331907)

---

Canonical: https://newsio.io/n/2dc77288-8bb3-4194-b4f2-efd03faef066/phase-3-trials-for-chronic-weight-management-planned-for-initiation-in-the-secon
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works